The new golden era for radioimmunotherapy: Not just for lymphomas anymore

Cancer Control

Volumn 20, Issue 1, 2013, Pages 60-71

  Tomblyn, Michael B ^a   Katin, Michael J ^b   Wallner, Paul E ^c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b 21ST CENTURY ONCOLOGY   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPROMAB PENDETIDE IN 111; CYTOTOXIC AGENT; EDRECOLOMAB; GEMCITABINE; HEPAMA 1; HUMAN MILK FAT GLOBULE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 425; MONOCLONAL ANTIBODY 81C6; MONOCLONAL ANTIBODY A 33; MONOCLONAL ANTIBODY BC 2; MONOCLONAL ANTIBODY BRE 3; MONOCLONAL ANTIBODY CC49; MONOCLONAL ANTIBODY CT84.66; MONOCLONAL ANTIBODY J591; MONOCLONAL ANTIBODY L6; MONOCLONAL ANTIBODY M170; MONOCLONAL ANTIBODY MN 14; MONOCLONAL ANTIBODY MOV18; MONOCLONAL ANTIBODY NP 4; MONOCLONAL ANTIBODY OC125; MONOCLONAL ANTIBODY PAM4; MONOCLONAL ANTIBODY TNT 1; PACLITAXEL; PERTUZUMAB; PLACENTAL LIKE ALKALINE PHOSPHATASE; TEMOZOLOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN CANCER; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; HEMATOLOGIC DISEASE; HUMAN; IMMUNOGENICITY; ISOTOPE LABELING; LIVER CELL CARCINOMA; LIVER METASTASIS; LOW DRUG DOSE; LUNG CANCER; LYMPHOMA; MAXIMUM TOLERATED DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN LOCALIZATION; RADIATION DOSE; RADIOIMMUNOTHERAPY; RECURRENT CANCER; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC DISEASE; TUMOR VOLUME; UTERINE CERVIX CANCER;

EID: 84871580811     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481302000109     Document Type: Review

References (181)

1. Pressman D, Korngold L. The in vivo localization of anti-Wagnerosteogenic- sarcoma antibodies. Cancer. 1953;6(3):619-623.
2. Order SE, Stillwagon GB, Klein JL, et al. Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study. J Clin Oncol. 1985;3(12):1573-1582.
3. Goldenberg DM, DeLand F, Kim E, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med. 1978;298(25):1384-1386.
4. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495-497.
5. DeNardo SJ, Erickson KL, Benjamini E. Use of I-131 antibodies for radiation therapy. Clin Nucl Med. 1980; 5:S4-S5. Abstract.
6. DeNardo SJ, Erickson KL, Benjamini E, et al. Radioimmunotherapy for melanoma. Clin Cancer Res. 1981;29:434A. Abstract.
7. Carrasquillo JA, Krohn KA, Beaumier P, et al. Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep. 1984;68(1):317-328.
8. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43(5):693-713.
9. U.S. Food and Drug Administration, U.S. Department of Health & Human Services. Rituximab product approval letter, November 26, 1997. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm107740.pdf. Accessed November 12, 2012.
10. U.S. Food and Drug Administration, U.S. Department of Health & Human Services. Ibritumomab tiuxetan product approval letter, February 19, 2002. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm113489.pdf. Accessed November 12, 2012.
11. U.S. Food and Drug Administration, U.S. Department of Health & Human Services. Tositumomab and iodine I 131 tositumomab product approval information, June 27, 2003. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080503.htm. Accessed November 12, 2012.
12. Tomblyn M, Elstrom R, Himelstein AL, et al. Novel combination of anti-CD22 radioimmunotherapy and anti-CD20 immunotherapy targeting two different antigens in non-Hodgkin lymphoma (NHL): initial clinical experience. J Nucl Med. 2012;53(suppl 1). Abstract 500.
13. Tomblyn M. Radioimmunotherapy for B-cell non-Hodgkin lymphomas. Cancer Control. 2012;19(3):196-203.
14. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43(5):693-713.
15. American Cancer Society. Cancer Facts & Figures 2012. Atlanta, GA: American Cancer Society; 2012. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf. Accessed November 12, 2012.
16. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
17. Blumenthal RD, Sharkey RM, Kashi R, et al. Comparison of therapeutic efficacy and host toxicity of two different 131I-labelled antibodies and their fragments in the GW-39 colonic cancer xenograft model. Int J Cancer. 1989;44(2):292-300.
18. Blumenthal RD, Sharkey RM, Haywood L, et al. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies. Cancer Res. 1992;52(21):6036-6044.
19. Sharkey RM, Blumenthal RD, Behr TM, et al. Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma. Int J Cancer. 1997;72(3):477-485.
20. Behr TM, Memtsoudis S, Sharkey RM, et al. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. Int J Cancer. 1998;77(5):787-795.
21. Behr TM, Sharkey RM, Juweid MI, et al. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors. Cancer Res. 1996;56(8):1805-1816.
22. Sgouros G. Radioimmunotherapy of micrometastases: sidestepping the solid-tumor hurdle. J Nucl Med. 1995;36(10):1910-1912.
23. Behr TM, Salib AL, Liersch T, et al. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study. Clin Cancer Res. 1999;5(10 suppl):3232s-3242s.
24. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med. 1965;121:439-462.
25. Lane DM, Eagle KF, Begent RH, et al. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies. Br J Cancer. 1994;70(3):521-525.
26. Behr TM, Sharkey RM, Juweid ME, et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med. 1997;38(6):858-870.
27. Juweid ME, Sharkey RM, Behr T, et al. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2. J Nucl Med. 1996;37(9):1504-1510.
28. Juweid M, Sharkey RM, Swayne LC, et al. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer. J Nucl Med. 1998;39(1):34-42.
29. Hajjar G, Sharkey RM, Burton J, et al. Phase I radioimmunotherapy trial with iodine-131-labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer. 2002;2(1):31-42.
30. Behr TM, Liersch T, Greiner-Bechert L, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer. 2002;94(4 suppl):1373-1381.
31. Liersch T, Meller J, Bittrich M, et al. Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol. 2007;14(9):2577-2590.
32. Liersch T, Meller J, Bittrich M, et al. Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol. 2007;14(9):2577-2590.
33. Liersch T, Meller J, Sahlmann C, et al. Repeated anti-CEA-radioimmunotherapy (RAIT) with 131iodine-labetuzumab (phase II study) versus single dose RAIT after salvage resection of colorectal liver metastases (CRC-LM). J Clin Oncol. 2008;26(20 suppl):4080. Abstract.
34. Beatty JD, Duda RB, Williams LE, et al. Preoperative imaging of colorectal carcinoma with 111In-labeled anticarcinoembryonic antigen monoclonal antibody. Cancer Res. 1986;46(12 Pt 1):6494-6502.
35. Wong JYC, Chu DZ, Yamauchi DM, et al. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res. 2000;6(10):3855-3863.
36. Wong JY, Chu DZ, Williams LE, et al. A phase I trial of (90)Y-DOTAanti- CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. Cancer Biother Radiopharm. 2006; 21(2):88-100.
37. Wong JY, Shibata S, Williams LE, et al. A phase I trial of 90Y-anticarcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res. 2003;9(16 Pt 1):5842-5852.
38. Shibata S, Raubitschek A, Leong L, et al. A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies. Clin Cancer Res. 2009;15(8):2935-2941.
39. Behr TM, Sharkey RM, Juweid ME, et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med. 1997;38(6):858-870.
40. Juweid ME, Sharkey RM, Behr T, et al. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2. J Nucl Med. 1996;37(9):1504-1510.
41. Ychou M, Pelegrin A, Faurous P, et al. Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab') 2 in patients with non-resectable liver metastases from colorectal cancer. Int J Cancer. 1998;75(4):615-619.
42. Ychou M, Azria D, Menkarios C, et al. Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab') 2 after resection of liver metastases from colorectal cancer. Clin Cancer Res. 2008;14(11):3487-3493.
43. Gaya AM, Violet J, Dancey G, et al. A phase I/II trial of radioimmunotherapy with 131Iodine labelled A5B7 anti-CEA antibody (131I-A5B7) in combination with combretastatin-A4-phosphate (CA4P) in advanced gastrointestinal carcinomas. J Clin Oncol. 2008;26(20 suppl):14517. Abstract.
44. Yu B, Carrasquillo J, Milenic D, et al. Phase I trial of iodine 131- labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. J Clin Oncol. 1996;14(6):1798-1809.
45. Breitz HB, Weiden PL, Vanderheyden JL, et al. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials. J Nucl Med. 1992;33(6):1099-1109.
46. Divgi CR, Scott AM, Dantis L, et al. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Med. 1995;36 (4): 586-592.
47. Murray JL, Macey DJ, Kasi LP, et al. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer. Cancer. 1994;73(3 suppl):1057-1066.
48. Wheeler RH, Meredith RF, Saleh MN, et al. A phase II trial of IL-1 + radioimmunotherapy (RIT) in patients (pts) with metastatic colon cancer. J Clin Oncol. 1994;13:295. Abstract 959.
49. Mulligan T, Carrasquillo JA, Chung Y, et al. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res. 1995;1(12):1447-1454.
50. Tempero M, Leichner P, Dalrymple G, et al. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J Clin Oncol. 1997;15(4):1518-1528.
51. Tempero M, Leichner P, Baranowska-Kortylewicz J, et al. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res. 2000;6(8):3095-3102.
52. Meredith RF, Khazaeli MB, Plott WE, et al. Phase I trial of iodine- 131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med. 1992;33(1):23-29.
53. Markoe AM, Brady LW, Woo D, et al. Treatment of gastrointestinal cancer using monoclonal antibodies. Front Radiat Ther Oncol. 1990;24:214-227.
54. Meredith RF, Khazaeli MB, Plott WE, et al. Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. J Nucl Med. 1995;36(12):2229-2233.
55. Weiden PL, Breitz HB, Seiler CA, et al. Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10. J Nucl Med. 1993;34(12):2111-2119.
56. Welt S, Divgi CR, Kemeny N, et al. Phase I/II study of iodine 131- labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol. 1994;12(8):1561-1571.
57. Welt S, Scott AM, Divgi CR, et al. Phase I/II study of iodine 125- labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol. 1996;14(6):1787-1797.
58. Chong G, Lee FT, Hopkins W, et al. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res. 2005;11(13): 4818-4826.
59. Fisher B, Redmond C, Poisson R, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1989;320(13):822-828.
60. Sarrazin D, Lê MG, Arriagada R, et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol. 1989;14(3):177-184.
61. Wong JY, Somlo G, Odom-Maryon T, et al. Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer. Clin Cancer Res. 1999;5(10 suppl):3224s-3231s.
62. Major PP, Dion AS, Williams CJ, et al. Breast tumor radioimmunodetection with a 111In-labeled monoclonal antibody (MA5) against a mucin-like antigen. Cancer Res. 1990;50(3 suppl):927s-931s.
63. Kramer EL, DeNardo SJ, Liebes L, et al. Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I study. J Nucl Med. 1993;34(7):1067-1074.
64. Granowska M, Biassoni L, Carroll MJ, et al. Breast cancer 99mTc SM3 radioimmunoscintigraphy. Acta Oncol. 1996;35(3):319-321.
65. Baum RP, Brümmendorf TH. Radioimmunolocalization of primary and metastatic breast cancer. Q J Nucl Med. 1998;42(1):33-42.
66. Schrier DM, Stemmer SM, Johnson T, et al. High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial. Cancer Res. 1995;55(23 suppl):5921s-5924s.
67. Cagnoni PJ, Ceriani RL, Cole WC, et al. Phase I study of high-dose radioimmunotherapy with 90-Y-hu-BrE-3 followed by autologous stem cell support (ASCS) in patients with metastatic breast cancer. Cancer Biother Radiopharm. 1998;13(4):328. Abstract 92.
68. Marken JS, Schieven GL, Hellström I, et al. Cloning and expression of the tumor-associated antigen L6. Proc Natl Acad Sci U S A. 1992;89(8):3503-3507.
69. Richman CM, DeNardo SJ, O'Grady LF, et al. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res. 1995;55(23 suppl):5916s-5920s.
70. Denardo SJ, O'Grady LF, Richman CM, et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res. 1997;17(3B):1745-1751.
71. Macey DJ, Grant EJ, Kasi L, et al. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131Ilabeled monoclonal antibody CC49 in breast cancer: a phase II trial. Clin Cancer Res. 1997;3(9):1547-1555.
72. Murray JL, Macey DJ, Grant EJ, et al. Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment. Cancer Res. 1995;55(23 suppl):5925s-5928s.
73. Goldenberg DM, DeLand FH, Bennett SJ, et al. Radioimmunodetection of prostatic cancer. In vivo use of radioactive antibodies against prostatic acid phosphatase for diagnosis and detection of prostatic cancer by nuclear imaging. JAMA. 1983;250(5):630-635.
74. Meredith RF, Bueschen AJ, Khazaeli MB, et al, Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med. 1994;35(6):1017-1022.
75. Meredith RF, Khazaeli MB, Macey DJ, et al. Phase II study of interferon- enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res. 1999;5(10 suppl):3254s-3258s.
76. O'Donnell RT, DeNardo SJ, Shi XB, et al. L6 monoclonal antibody binds prostate cancer. Prostate. 1998;37(2):91-97.
77. O'Donnell RT, DeNardo SJ, DeNardo GL, et al. Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice. Prostate. 2000;44(3):187-192.
78. O'Donnell RT, DeNardo SJ, Miers LA, et al. Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Prostate. 2002;50(1):27-37.
79. DeNardo SJ, Richman CM, Albrecht H, et al. Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer. Clin Cancer Res. 2005;11(19 pt 2):7187s-7194s.
80. O'Donnell RT, DeNardo SJ, Yuan A, et al. Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clin Cancer Res. 2001;7(6):1561-1568.
81. Richman CM, Denardo SJ, O'Donnell RT, et al. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res. 2005;11(16):5920-5927.
82. Abdel-Nabi H, Wright GL, Gulfo JV, et al. Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Semin Urol. 1992;10(1):45-54.
83. Deb N, Goris M, Trisler K, et al. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res. 1996;2(8):1289-1297.
84. Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostatespecific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59(13):3192-3198.
85. McDevitt MR, Barendswaard E, Ma D, et al. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 2000;60(21):6095-6100.
86. Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium- labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23(21):4591-4601.
87. Milowsky MI, Nanus DM, Kostakoglu L, et al. Phase I trial of yttrium- 90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. 2004;22(13):2522-2531.
88. Vallabhajosula S, Kuji I, Hamacher KA, et al. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate- specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med. 2005;46(4):634-641.
89. Epenetos AA, Munro AJ, Stewart S, et al. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol. 1987;5(12):1890-1899.
90. Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer. 1993;68(2):403-406.
91. Verheijen RH, Massuger LF, Benigno BB, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol. 2006;24(4):571-578.
92. Oei AL, Verheijen RH, Seiden MV, et al. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer. 2007;120(12):2710-2714.
93. Benham FJ, Povey MS, Harris H. Placental-like alkaline phosphatase in malignant and benign ovarian tumors. Clin Chim Acta. 1978;86(2):201-215.
94. Sunderland CA, Davies JO, Stirrat GM. Immunohistology of normal and ovarian cancer tissue with a monoclonal antibody to placental alkaline phosphatase. Cancer Res. 1984;44(10):4496-4502.
95. Kosmas C, Kalofonos HP, Hird V, Epenetos AA. Monoclonal antibody targeting of ovarian carcinoma. Oncology. 1998;55(5):435-446.
96. Carter P, Presta L, Gorman CM, et al. Humanization of an antip185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992;89(10):4285-4289.
97. Crow DM, Williams L, Colcher D, et al. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti- CEA antibodies with taxol. Bioconjug Chem. 2005;16(5):1117-1125.
98. Rasaneh S, Rajabi H, Babaei MH, et al. 177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nucl Med Biol. 2010;37(8):949-955.
99. Chen KT, Lee TW, Lo JM. In vivo examination of (188)Re(I)-tricarbonyl- labeled trastuzumab to target HER2-overexpressing breast cancer. Nucl Med Biol. 2009;36(4):355-361.
100. Akabani G, Carlin S, Welsh P, et al. In vitro cytotoxicity of 211Atlabeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl Med Biol. 2006;33(3):333-347.
101. Palm S, Bäck T, Claesson I, et al. Therapeutic efficacy of astatine- 211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. Int J Radiat Oncol Biol Phys. 2007;69(2):572-579.
102. Milenic DE, Garmestani K, Brady ED, et al. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm. 2005;20(5):557-568.
103. Borchardt PE, Yuan RR, Miederer M, et al. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res. 2003;63(16):5084-5090.
104. Abbas N, Heyerdahl H, Bruland OS, et al. Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTAtrastuzumab. EJNMMI Res. 2011;1(1):18.
105. Meredith RF. Safety study of 212Pb-TCMC-trastuzumab radio immunotherapy. http://clinicaltrials.gov/ct2/show/NCT01384253. Accessed November 12, 2012.
106. Persson M, Gedda L, Lundqvist H, et al. [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Cancer Res. 2007;67(1):326-331.
107. Meredith RF, Partridge EE, Alvarez RD, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med. 1996;37(9):1491-1496.
108. Alvarez RD, Partridge EE, Khazaeli MB, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol. 1997;65(1):94-101.
109. Alvarez RD, Huh WK, Khazaeli MB, et al. A phase I study of combined modality (90)yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res. 2002;8(9):2806-2811.
110. Hnatowich D, Jhinol M, Siebecker DA, et al. Patient biodistribution of intraperitoneally administered yttrium-90-labeled antibody. J Nucl Med. 1988;29(8):1428-1435.
111. Mahé MA, Fumoleau P, Fabbro M, et al. A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin Cancer Res. 1999;5(10 suppl):3249s-3253s.
112. Muto MG, Finkler NJ, Kassis AI, et al. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. Gynecol Oncol. 1992;45(3):265-272.
113. Campbell IG, Jones TA, Foulkes WD, et al. Folate-binding protein is a marker for ovarian cancer. Cancer Res. 1991;51(19):5329-5338.
114. Molthoff CF, Buist MR, Kenemans P, et al. Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen. J Nucl Med. 1992;33(11):2000-2005.
115. Buist MR, Kenemans P, Molthoff CF, et al. Tumor uptake of intravenously administered radiolabeled antibodies in ovarian carcinoma patients in relation to antigen expression and other tumor characteristics. Int J Cancer. 1995;64(2):92-98.
116. van Zanten-Przybysz I, Molthoff CF, Roos JC, et al. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. Int J Cancer. 2001;92(1):106-114.
117. Welshinger M, Yin BW, Lloyd KO. Initial immunochemical haracterization of MX35 ovarian cancer antigen. Gynecol Oncol. 1997;67(2):188-192.
118. Yin BW, Kiyamova R, Chua R, et al. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer Immun. 2008;8:3.
119. Elgqvist J, Andersson H, Bäck T, et al. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: outcome related to measured tumor size and mean absorbed dose. J Nucl Med. 2006;47(8):1342-1350.
120. Elgqvist J, Andersson H, Bernhardt P, et al. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab') 2. Int J Radiat Oncol Biol Phys. 2006;66(4):1228-1237.
121. Elgqvist J, Andersson H, Jensen H, et al. Repeated intraperitoneal alpha-radioimmunotherapy of ovarian cancer in mice. J Oncol. 2010;2010:394913.
122. Andersson H, Cederkrantz E, Bäck T, et al. Intraperitoneal alphaparticle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2 - a phase I study. J Nucl Med. 2009; 50(7):1153-1160.
123. Jacobs AJ, Fer M, Su FM, et al. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response. Obstet Gynecol. 1993;82(4 pt 1):586-593.
124. Turner JH, Rose AH, Glancy RJ, et al. Orthotopic xenografts of human melanoma and colonic and ovarian carcinoma in sheep to evaluate radioimmunotherapy. Br J Cancer. 1998;78(4):486-494.
125. Kievit E, Pinedo HM, Schlüper HM, et al. Comparison of monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts. Br J Cancer. 1996;73(4):457-464.
126. Davies Q, Perkins AC, Roos JC, et al. An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma. Br J Obstet Gynaecol. 1999;106(1):31-37.
127. Molthoff CF, Pinedo HM, Schlüper HM, et al. Influence of dose and schedule on the therapeutic efficacy of 131I-labelled monoclonal antibody 139H2 in a human ovarian cancer xenograft model. Int J Cancer. 1992;50(3):474-480.
128. Knör S, Sato S, Huber T, et al. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Eur J Nucl Med Mol Imaging. 2008;35(1):53-64.
129. Song EY, Abbas Rizvi SM, Qu CF, et al. Pharmacokinetics and toxicity of (213)Bi-labeled PAI2 in preclinical targeted alpha therapy for cancer. Cancer Biol Ther. 2007;6(6):898-904.
130. Steffen AC, Almqvist Y, Chyan MK, et al. Biodistribution of 211At labeled HER-2 binding affibody molecules in mice. Oncol Rep. 2007;17(5):1141-1147.
131. Tolmachev V, Orlova A, Pehrson R, et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 2007;67:2773-2782.
132. Moertel CG, Childs DS Jr, Reitemeier RJ, et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969;2:865-867.
133. Gold DV, Alisauskas R, Sharkey RM. Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4. Cancer Res. 1995;55:1105-1110.
134. Mariani G, Molea N, Bacciardi D, et al. Initial targeting, biodistribution and pharmacokinetics screening of the monoclonal antibody PAM4 for immunoscintigraphy in patients with pancreatic cancer. Cancer Res. 1995;55:5911s-5915s.
135. Gold DV, Vardi Y, Ying Z, et al. Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled PAM4 antibody. Int J Cancer. 1997;71:660-667.
136. Cardillo TM, Ying Z, Gold DV. Therapeutic advantage of 90yttriumversus 131iodine-labeled PAM4 antibody in experimental pancreatic cancer. Clin Cancer Res. 2001;7:3186-3192.
137. Gold DV, Schutsky K, Modrak D, et al. Low-dose radioimmunotherapy (90Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer. Clin Cancer Res. 2003;9:3929S-3937S.
138. Gulec SA, Cohen SJ, Pennington KL, et al. Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I singledose escalation trial. Clin Cancer Res. 2011;17:4091-4100.
139. Goldsmith S, Manzone T, Holt M, et al. Final results of a phase I/II study of 90Y-clivatuzumab tetraxetan (90Y-hPAM4) plus gemcitabine (Gem) in advanced pancreatic cancer (APC). J Nucl Med. 2012;53(suppl 1). Abstract 495.
140. Wegener WA. A study of fractionated 90Y-hPAM4 plus gemcitabine in pancreatic cancer patients receiving at least 2 prior therapies. http://clinicaltrials.gov/ct2/show/NCT01510561. Accessed November 12, 2012.
141. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42:S206-S214.
142. Finn RS. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Cancer Res. 2010;16:390-397.
143. Liu YK, Yang KZ, Wu YD, et al. Treatment of advanced primary hepatocellular carcinoma by 131-I-anti-AFP. Lancet. 1983;1:531-532.
144. Sitzmann JV, Abrams R. Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. Ann Surg. 1993;217:149.
145. Shi L, Wu M, Chen H. Radioimmunoimaging (RII) and radioimmunotherapy (RIT) of human primary hepatic cancer (hPHC) with anti-PHC monoclonal antibody in tumor-bearing nude mice. Zhonghua Zhong Liu Za Zhi. 1995;17:20-23.
146. Chen S, Li B, Xie H, et al. Phase I clinical trial of targeted therapy using 131I-Hepama-1 mAb in patients with hepatocellular carcinoma. Cancer Biother Radiopharm. 2004;19:589-600.
147. Chen Z-N, Mi L, Xu J, et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys. 2006;65:435-444.
148. Zhang Z, Bian H, Feng Q, et al. Biodistribution and localization of iodine-131-labeled metuximab in patients with hepatocellular carcinoma. Cancer Biol Ther. 2006;5:318-322.
149. Kalofonos HP, Pawlikowska TR, Hemingway A, et al. Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies directed against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med. 1989;30:1636-1645.
150. Qin DX, Zheng R, Tang J, et al. Influence of radiation on the bloodbrain barrier and optimum time of chemotherapy. Int J Radiat Oncol Biol Phys. 1990;19:1507-1510.
151. Quang TS, Brady LW. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of highgrade brain gliomas. Int J Radiat Oncol Biol Phys. 2004;58:972-975.
152. Cao Y, Tsien CI, Shen Z, et al. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol. 2005;23:4127-4136.
153. Wikstrand CJ, Fung KM, Trojanowski JQ, et al. Immunohistochemistry and antigens of diagnostic significance. In: Bigner DD, McLendon RE, Bruner JM, eds. Russell and Rubinstein's Pathology of the Nervous System. 6th ed. New York, NY: Oxford University Press; 1998:251-304.
154. Riva P, Arista A, Sturiale C, et al. Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labelled anti-tenascin monoclonal antibody BC-2. Int J Cancer. 1992;51:7-13.
155. Riva P, Arista A, Tison V, et al. Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors. Cancer. 1994;73:1076-1082.
156. Riva P, Arista A, Franceschi G, et al. Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res. 1995;55:5952-5956.
157. Riva P, Franceschi G, Frattarelli M, et al. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study. Clin Cancer Res. 1999;5:3275s-3280s.
158. Riva P, Franceschi G, Riva N, et al. Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med. 2000;27:601-609.
159. Bigner DD, Brown MT, Friedman AH, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol. 1998;16:2202-2212.
160. Cokgor I, Akabani G, Kuan CT, et al. Phase I trial results of iodine- 131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2000;18:3862-3872.
161. Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002;20:1389-1397.
162. Akabani G, Reardon DA, Coleman RE, et al. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med. 2005;46:1042-1051.
163. Reardon DA, Akabani G, Coleman RE, et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol. 2006;24:115-122.
164. Reardon DA, Quinn JA, Akabani G, et al. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. J Nucl Med. 2006;47:912-918.
165. Marquez A, Wu R, Zhao J, et al. Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn Mol Pathol. 2004;13(1):1-8.
166. Brady LW, Markoe AM, Woo DV, et al. Iodine125 labeled anti-epider mal growth factor receptor-425 in the treatment of malignant astrocytomas: apilot study. J Neurosurg Sci. 1990;34:243-249.
167. Brady LW, Miyamoto C, Woo DV, et al. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys. 1992; 22:225-230.
168. Li L, Quang TS, Gracely EJ, et al. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg. 2010;113:192-198.
169. Kramer K, Cheung NK, Humm JL, et al. Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8. Med Pediatr Oncol. 2000;35:716-718.
170. Kramer K, Humm JL, Souweidane MM, et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol. 2007;25:5465-5470.
171. Mason DY, Biberfeld P. Technical aspects of lymphoma immunohistology. J Histochem Cytochem. 1980;28:731-745.
172. Taylor CR. Immunohistologic studies of lymphomas: new methodology yields new information and poses new problems. J Histochem Cytochem. 1979;27:1189-1191.
173. Epstein AL, Chen F-M, Taylor CR. A novel method for the detection of necrotic lesions in human cancers. Cancer Res. 1988;48:5842-5848.
174. Epstein AL, Chen D, Ansari A, et al. Radioimmunodetection of necrotic lesions in human tumors using I-131 labeled TNT-1 F(ab')2 monoclonal antibody. Antibody Immunoconjugates Radiopharm. 1991;4:151-161.
175. Chen S, Yu L, Jiang C, et al. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol. 2005;23:1538-1547.
176. Patel SJ, Shapiro WR, Laske DW, et al. Safety and feasibility of convection- enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery. 2005;56:1243-1252.
177. Street HH, Goris ML, Fisher GA, et al. Phase I study of 131I-chimeric (ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. Cancer Biother Radiopharm. 2006;21:243-256.
178. Yu L, Chen T, Li Z, et al. 131I-ch-TNT-3 radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother Radiopharm. 2006;21:5-14.
179. Anderson PM, Wiseman GA, Lewis BD, et al. A phase I safety and imaging study using radiofrequency ablation (RFA) followed by 131I-chTNT- 1/B radioimmunotherapy adjuvant treatment of hepatic metastases. Cancer Ther. 2003;1:297-306.
180. Wang H, Cao C, Li B, et al. Immunogenicity of iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients. Cancer Immunol Immunother. 2008;57(5):677-684.
181. Finkelstein SE, Fishman M. Clinical opportunities in combining immunotherapy with radiation therapy. Front Oncol. 2012;2:169. Epub 2012 November 26.